Votes at a glance: committee reports SB401, SB387, SB369 and SB323 out of Senate Insurance Committee
Loading...
Summary
On April 1 the committee reported SB401 (PDAB), SB387 (PBM reform), SB369 (OGB pricing) and SB323 (PBM penalties) out of committee with amendments. SB401 and SB387 were reported with linked provisions and sunset language; SB369 was narrowed to state‑sponsored plans and is expected to receive a fiscal analysis.
The Senate Insurance Committee reported four bills out of committee on April 1, 2026: SB401 (Prescription Drug Affordability Board), SB387 (PBM reforms), SB369 (Office of Group Benefits pricing), and SB323 (PBM penalties). All were reported by voice consent after adopted amendments and extended testimony.
- SB401 (reported as amended): Creates a Prescription Drug Affordability Board to collect manufacturer pricing and market information; committee adopted technical edits, merged related language, required manufacturer explanations for certain brand‑name price increases and added a sunset (06/30/2028). (Motion to report made by Chairman Talbot; outcome: reported as amended.)
- SB387 (reported as amended): PBM reform package that added audit look‑back limits, consolidated pharmacy appeals, fiduciary‑style duties to prioritize enrollees, requirements for rebate pass‑through to plan sponsors, restrictions on rebate‑driven formulary placement, and audit authority across corporate affiliates; the bill was linked to SB401. (Motion to report made by Sen. Bass; outcome: reported as amended.)
- SB369 (reported as amended): Pricing authority or benchmarking language focused on the Office of Group Benefits; amendment 15‑41 clarified the bill applies to OGB and other state‑sponsored plans (not the wider commercial market). The committee noted a fiscal note will be required for finance referral. (Motion to report made by Sen. Bass; outcome: reported as amended.)
- SB323 (reported favorably): Increases civil penalties for PBM violations to $25,000 per claim, removes the previous aggregate cap and allows the commissioner to issue cease‑and‑desist orders in ongoing violation cases. (Motion to report made by Sen. Bass; outcome: reported favorably.)
Committee action was by voice consent with no recorded roll‑call votes; sponsors said they will work on technical, fiscal and confidentiality details between committee and floor. The bills will proceed to the next stages of the legislative process.
